Consistently, analysis of scRNA-seq data from metastatic melanoma patients treated with either anti-PD1 or anti-PD1+anti-CTLA4 (9), highlighted the increased abundance of CD38-expressing CD8+ T cells in patients non-responding to ICB therapy, as previously reported (17). The gene discussed is CTLA4; the disease is metastatic melanoma.